Assessing the De Novo Paradigm in Sporadic Early-Onset Alzheimer Disease Trios

Why It Matters

The findings reshape genetic testing strategies for EOAD, emphasizing inherited polygenic risk over rare de novo mutations and guiding more cost‑effective counseling for patients and families.

Key Takeaways

• Three sporadic EOAD cases had de novo APP or PSEN1 pathogenic variants.
• Exome sequencing identified 53 DNMs across 46 trios, few in AD‑related genes.
• Candidate DNMs in DDR1 and SPHK2 suggest new pathways for Aβ toxicity.
• Inherited rare risk variants were present in 48% of probands.
• Trio‑based sequencing showed limited utility compared with proband‑only testing.

Pulse Analysis

Early‑onset Alzheimer disease (EOAD) accounts for a small but clinically important fraction of dementia, often presenting before age 65. While autosomal‑dominant mutations in APP, PSEN1 and PSEN2 explain roughly 12% of EOAD, the genetic architecture of the remaining sporadic cases remains elusive. De novo mutations—genetic changes that arise spontaneously in the patient—have been implicated in several neurodegenerative disorders, prompting researchers to explore whether they also contribute to EOAD. Trio‑based sequencing, which compares the genomes of a patient and both unaffected parents, offers a direct route to uncover such events, but its feasibility in adult‑onset diseases has been uncertain due to challenges in obtaining parental DNA and the heterogeneous nature of disease risk.

In this French cohort, investigators recruited 49 sporadic EOAD trios, performed targeted screening for known dominant genes, and then applied high‑coverage exome sequencing to all participants, with a subset undergoing whole‑genome sequencing. The study confirmed three pathogenic de novo mutations in APP or PSEN1, reinforcing the relevance of these classic genes even in apparently sporadic cases. Beyond these, 53 additional DNMs were catalogued, including novel missense changes in DDR1 and an in‑frame indel in SPHK2—both genes linked to amyloid‑beta processing or microglial activation. However, rigorous burden testing across a large case‑control dataset failed to demonstrate a statistically significant excess of rare variants near these DNMs, suggesting that most de novo events are either benign or have effects too subtle to detect with current sample sizes.

The practical takeaway for clinicians and genetic counselors is clear: routine trio‑based sequencing is unlikely to yield actionable findings for the majority of sporadic EOAD patients. Instead, a proband‑focused approach—leveraging dementia panels, exome, or genome sequencing—combined with assessment of inherited risk variants (such as APOE‑ε4 and rare alleles in SORL1, TREM2, ABCA7) provides a more efficient diagnostic pathway. As sequencing technologies evolve, especially long‑read platforms capable of capturing structural variants and repeat expansions, future studies may uncover additional genetic contributors. For now, the emphasis should remain on integrating polygenic risk scores and known rare risk alleles into personalized care plans for early‑onset Alzheimer patients.